VoxNeuro

VoxNeuro operates at the intersection of neurotechnology, medical-device software, diagnostics, and digital health. Its product focus is Cognitive Function Neuroimaging (cfNI), which aims to give clinicians objective, quantitative measures of brain function and structured reports that can be reviewed alongside other clinical information. The website describes the software as an FDA-cleared Class II medical device for prescription use, distinguishing its positioning from general wellness or consumer brain-training tools. It is designed for administration by existing clinical staff, and the company says training can take days rather than weeks. VoxNeuro also describes reimbursement through established CPT codes, including commercial insurance and Medicare, which may be relevant to adoption economics. Its disclosed category peers are therefore best understood as the broader field of clinical cognitive assessment, neurodiagnostics, and medical software. The September 2026 collaboration with Diagnostic Imaging Centers of Texas points to a workflow-oriented approach: pairing brain-function assessment with imaging services rather than positioning the software as a standalone consumer product.

VoxNeuro’s disclosed trajectory shows a progression from early grants and support to seed financing, a corporate round, regulatory progress, and clinical deployment. Its funding history begins with a CAD 249,000 grant announced on Sep 24, 2019, followed by non-equity assistance in 2020, a corporate round in October 2020, and two seed rounds announced in 2021 and 2022. The largest individually disclosed round was a CAD 4.5 million corporate round on Aug 3, 2023, led by G.Tec Medical Engineering; the company’s stated total funding is approximately US$8.02 million. The 2026 FDA clearance is a significant inflection point because it advances the product’s regulatory standing in the US market. The September 2026 collaboration with Diagnostic Imaging Centers of Texas, followed by coverage of the integration on October 1, provides a concrete example of deployment through an existing clinical provider. These milestones suggest a shift from product development and financing toward market access and workflow integration. Employee-growth evidence is limited: the profile lists an 11–50 employee range but does not provide a hiring trend, and only one current position is identified.